amantadine / Generic mfg. - LARVOL DELTA

Investigating on Therapeutic Potential of Amantadine in mitigation of Burn Injury-Induced Chronic Pain (NeuPSIG 2025) - No abstract available

CNS Disorders • Pain

Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice. (PubMed, An Acad Bras Cienc) - "Prior to bee venom (BV) or amantadine treatment, mice received medial forebrain bundle microinjections of 6-hydroxydopamine or ascorbate saline...The chemical composition of BV was also assessed, identifying the highest concentrations of apamin, phospholipase A2 and melittin and the antioxidant activity. Treatment with BV at a dose of 0.1mg.kg-1 reduced apomorphine-induced rotations, increased the number of contralateral contacts to the lesion, and increased grip strength, restoring motor control impaired by LIDs, indicating potential therapeutic efficacy."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Bat Influenza M2 Shows Functions Similar to Those of Classical Influenza A Viruses. (PubMed, Pathogens) - "Here, we show that the bat influenza M2 amino acid at position 31 (N/S) is critical for sensitivity to antivirals targeting the ion channel such as amantadine and other tested antivirals and that the amino acids at position 37 (H/G) and 41 (W/A) are crucial for virus replication and survival. The results indicate that bat influenza M2 functions similarly to conventional IAVs despite the low identity between the two."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Neural dysfunction, inflammatory disorder, and metabolic interference feature in amantadine-related adverse drug events: a perspective from FAERS and network toxicology. (PubMed, Expert Opin Drug Saf) - "Molecular docking revealed high-affinity binding of amantadine to MAPK1, MAPK3, HSP90AA1, CYP3A4, and CYP2C19 which were involved in neural function, inflammation, and metabolism. The mechanisms underlying amantadine-related ADEs allow new insights into pharmacovigilance for amantadine use."

Adverse events • Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • CDC37 • CYP2C19 • CYP3A4 • HSP90AA1 • MAPK1 • MAPK3 • PDGFRB • STAT3

Aqueous extracts of Portulaca oleracea L. alleviate atopic dermatitis by restoring skin barrier function. (PubMed, Front Pharmacol) - "Amantadine acetate was identified as an abundant ingredient and further predicted to be a Janus kinase 1 (JAK1) inhibitor via molecular binding simulation...PO significantly ameliorated skin lesions and restored epidermal barrier function in AD mice. This was achieved by suppressing JAK1 enzymatic activity and JAK1-mediated STAT signaling pathways."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • CD4 • FLG • JAK1 • STAT3 • STAT6

CHANTER syndrome in a cocaine positive patient. (PubMed, Radiol Case Rep) - "The patient was treated with high-dose thiamine, folate, amantadine, modafinil and was discharged to a long term acute care facility. Possible mechanisms of injury are explored such as damage from vasospasm, vasoconstriction, impairment of dopamine and glutamate neurotransmission, oxidative stress from cocaine metabolites, and direct mitochondrial damage. This case adds to a newly established growing body of literature on CHANTER syndrome to support future diagnosticians in reviewing patients with characteristic neuroimaging findings and a recent history of cocaine use."

Journal • Critical care

COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. (PubMed, Healthcare (Basel)) - " These findings suggest a potential protective effect of ACEI, ARBs, and amantadine against severe COVID-19 and support the safety and continuity of these treatments. Multicentric studies incorporating post-COVID syndrome data are needed to validate these observations if hospitalizations persist."

Journal • Infectious Disease • Novel Coronavirus Disease

MND-SMART: Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (clinicaltrials.gov) - P2/3 | N=1150 | Recruiting | Sponsor: University of Edinburgh | N=800 ➔ 1150 | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Sep 2026 ➔ Dec 2030

Enrollment change • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

Reevaluating Electroencephalography Monitoring in Koolen-de Vries Syndrome: A Case of Delayed Focal Impaired Consciousness Seizure Diagnosis. (PubMed, Cureus) - "He was then treated accordingly with diazepam and amantadine, which led to a significant improvement in neurological status. This case highlights the importance of the use of EEG in KdVS patients, as well as the implications of implementing guidelines recommending the low threshold required for use of EEG and full neurological work-up for patients with any alarm symptoms possibly indicative of FICS or other epileptiform activity."

Journal • CNS Disorders • Epilepsy • Genetic Disorders • Pediatrics • KANSL1

Gait Analysis in Neurological Disease (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Progressive Supranuclear Palsy

Body burden and health risk of pharmaceuticals in elderly population: A multi-site biomonitoring study in China. (PubMed, Ecotoxicol Environ Saf) - "Amoxicillin, florfenicol, and ciprofloxacin were major contributors to the potential health risk of gut microbiota disruption. Among the non-antibiotic PhACs, acetaminophen, amantadine, and metformin posed potential health risks to 2.2 %, 1.9 %, and 0.9 % of all individuals, respectively. Overall, this study sheds light on PhAC exposure in older adults across different regions and provides valuable insights that can help with safeguarding their health."

Journal

Synthesis, characterization and antidiabetic studies of novel amantadine-derived Schiff base (AHB) and its Zn(ii), Co(ii), Cr(iii) and VO(iv) complexes. (PubMed, RSC Adv) - "Among all prepared compounds, the Zn(ii) complex was found to be a good α-glucosidase inhibitor comparable to the standard (acarbose), while other complexes showed a moderate inhibition of α-glucosidase. Both Cr(iii) and Co(ii) complexes were found to be effective α-amylase inhibitors. Based on the current findings, it can be anticipated that the synthesized compounds can be tried as effective therapeutic agents to cure diabetes mellitus."

Journal • Diabetes • Metabolic Disorders

Liquiritigenin-Rich Hydroalcoholic Extract of Brazilian Red Propolis Reduces Dyskinesia Induced by 3,4- Dihydroxyphenylalanine in Hemiparkinsonian Rats. (PubMed, Basic Clin Pharmacol Toxicol) - "HERP presented a high antioxidant effect in vitro, while in vivo the locomotive, orolingual, limb and axial dyskinetic effects of L-DOPA were counteracted with 10 mg/kg of HERP and 40 mg/kg of amantadine (AMAN)...HERP decreased the ipsilateral loss of TH expression, whereas HERP and AMAN increased contralateral expression of TH at the mesencephalon. HERP induced antidyskinetic effects in rats, with motor improvement, which is an advancement in comparison to standard medications, and these effects may be mediated by astrocyte-related mechanisms."

Journal • Preclinical • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • FAP • GFAP

Designing anti-bacterial supramolecular gels from primary ammonium dicarboxylate (PAD) salts for self-delivery applications. (PubMed, Faraday Discuss) - "Synthesis, structure and supramolecular gelation behaviour of 20 PAD salts derived from 5 dicarboxylic acids - (CH2)n-(COOH)2 (n = 4, 7, 10, 12 and 14) - and 4 therapeutic amines - amantadine (AMN), tyramine (TRM), tryptamine (TRP) and mafenide (MAF) - are reported. Detailed biological studies suggested that the C14·2MAF anti-bacterial property is caused by bacterial cell membrane disruption and ROS generation. Gradual release of C14·2MAF from a MS-gel bed and sheer thinning of the gel phase, clearly indicated that the C14·2MAF MS gel has potential use as a supramolecular topical gel for anti-bacterial treatment."

Journal

Antiviral activity of newly synthesized pyrazole derivatives against Newcastle disease virus. (PubMed, Sci Rep) - "Molecular docking simulation targeting immune receptor TLR4 protein (PDB ID: 3MU3) revealed that compound 6 achieved the highest docking score, surpassing both the reference drug (amantadine) and the co-crystallized ligand (LP4), primarily through hydrophobic interactions with PHE 46 residue...Impressively, the compounds also demonstrated desirable drug-likeness profiles. These findings suggest that the synthesized compounds hold promise as potent antiviral candidates."

Journal • TLR4

Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders. (PubMed, Pharmaceuticals (Basel)) - "Interestingly, several medications, including fluvoxamine (an antidepressant), dextromethorphan (a cough suppressant), and amantadine (an antiviral), which were initially developed for unrelated indications, have shown encouraging results in neurodegenerative therapy through S1R activation. Furthermore, as a synergistic benefit, combining S1R-targeting drugs with other therapeutic agents may also improve treatment efficacy. In this review, we highlight key repurposed drugs targeting S1R and explore their mechanisms of action, shedding light on their emerging therapeutic potential in the fight against neurodegeneration."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cough • Huntington's Disease • Movement Disorders • Parkinson's Disease • Respiratory Diseases

Treatment of Catatonia in Bipolar 1 Disorder With NMDA-Receptor Antagonist Memantine: A Case Series (APA 2025) - "While benzodiazepines and electroconvulsive therapy (ECT) remain standard treatments, treatment resistant alternatives like NMDA-receptor antagonists' amantadine and memantine continue to be explored...Lorazepam challenge test led to excessive sedation and limited clinical response for both patients and were unable to receive ECT due to limited resources...After a week on memantine and risperidone 1 mg twice daily, Mr...C experienced a more fluctuating course of symptoms while on memantine and olanzapine 5 mg... This case series demonstrates tolerability and successful use of memantine as an alternative treatment for catatonia secondary to bipolar I disorder. Our findings also demonstrated a faster therapeutic response time in the younger male patient. Limitations include lack of long-term follow-up."

Clinical • Anesthesia • Bipolar Disorder • CNS Disorders • Epilepsy • Immunology • Mood Disorders • Psychiatry • Schizophrenia

Social Determinants of Health in Low Resource Setting Through the Lens of Catatonia (APA 2025) - "The patient ultimately received treatment with lorazepam augmented with valproic acid, memantine, and zolpidem and only achieved partial remission...While awaiting approval, amantadine and zolpidem were utilized as augmentation strategies... This case series highlights patients who, due to legal, financial, and structural barriers, could not access gold standard catatonia therapy and were instead treated with less researched alternatives."

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Head Hits and Mind Tricks: A Literature Review of TBI and Psychosis" (APA 2025) - "Quetiapine and second-generation antipsychotics are preferred for their lower risk of side effects. The link between TBI/PCS and psychosis is complex, with TBI potentially leading to various psychotic symptoms. Functional neuroimaging, like SPECT, helps differentiate between schizophrenia-like and delusional TBI-related psychosis. Treatment is challenging due to the overlap of psychotic and cognitive symptoms."

Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Pain • Psychiatry • Schizophrenia • Sleep Disorder • Vascular Neurology

The Presence of an Absence: Withdrawal of Dopaminergic Medications Leading to Neuroleptic Malignant Syndrome (ATS 2025) - "The patient's family admitted confusion regarding his home PD medications (including both carbidopa/levodopa and amantadine) in the setting of multiple, differing prescriptions...Next, the supportive, ICU care necessary included common interventions and also rare interventions like dantrolene. Finally, non-oral PD formulations or carbidopa/levodopa ODT may help prevent NMS in acute ill PD patients with severe dysphagia. Hospital pharmacies should strategically stock at least one form of them."

Acute Kidney Injury • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease

Amantadine-Induced Hypoglycemia in a Patient Without a History of Diabetes Mellitus (ATS 2025) - "This abstract is funded by: none Introduction : Hypoglycemia, a state of low blood glucose, has multiple etiologies with the most common being drug-induced hypoglycemia particularly in individuals with a history of diabetes with insulin, sulfonylureas, and metformin as the most frequent offenders. Amantadine was discontinued with notable stable improvement in blood glucose levels.Discussion : Amantadine has been demonstrated to decrease glucagon levels and increase insulin levels which could potentially lead to hypoglycemia.3 While the etiology of hypoglycemia in this case is possibly multifactorial given the recent decreased PO intake, infection and poor reserves, Amantadine as a possible culprit was highly likely given the negative work up for other instigating factors. In essence, this case highlights the importance of comprehensive history taking and medication reconciliation in hospitalized patients."

Clinical • Asthma • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Endocrine Disorders • Epilepsy • Glaucoma • Hypoglycemia • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Multiple Sclerosis • Ophthalmology • Osteoporosis • Parkinson's Disease • Pneumonia • Psychiatry • Respiratory Diseases • Rheumatology • Schizophrenia

Chitosan-coated nanostructured lipid carriers of amantadine for nose-to-brain delivery: formulation optimization, in vitro-ex vivo characterization, and in vivo anti-parkinsonism assessment. (PubMed, Int J Biol Macromol) - "AMH-NLCs showed high cell viability (88.23 ± 7.49 %) in comparison to AMH-Sol (62.14 ± 6.81 %) on H2O2 induced PC12 cells at a concentration level of 100 μg/ml. In vivo studies exhibited effectiveness of CH-AMH-NLCs and AMH-NLCs and showed increased response when compared with amantadine solution (pure form) and marketed formulation."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Exploring the Risk of Adverse Drug Events in Combination with antiparkinsonics and antipsychotics - a two-decade real-world pharmacovigilance analysis based on the FAERS database. (PubMed, Int J Neuropsychopharmacol) - "During the combined application of antiparkinsonics and AP, in addition to ADEs such as movement disorders and emerging mental symptoms, the risks of infection and inflammation should also be given key attention. Long-term follow-up should run through the entire process of disease diagnosis and treatment, and attention should be paid to the influence of drug dosage forms and dosages. The medication plan should be adjusted in a timely manner when ADEs occur."

Adverse events • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Infectious Disease • Inflammation • Movement Disorders • Nephrology • Parkinson's Disease • Psychiatry • Urology

Safety Profile of Amantadine: A Comprehensive Analysis of Real-World Adverse Events from the FDA Adverse Event Reporting System Database. (PubMed, Curr Drug Saf) - "The study revealed significant safety concerns with amantadine, especially regarding nervous and psychiatric reactions. It highlighted the need for careful monitoring in clinical use and further research to understand mechanisms, enhance therapeutic outcomes, and minimize adverse events."

Adverse events • Journal • Real-world evidence • CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Vascular Neurology • ROR1

Genetic diversity of A(H5N1) avian influenza viruses isolated from birds and seals in Russia in 2023. (PubMed, Sci Rep) - "Seven viruses had genetic markers of amantadine resistance. All the influenza A(H5N1) viruses studied showed a binding preference for α2-3-linked sialic acids, suggesting a low risk of transmission among humans. Nevertheless, monitoring of reassortment and mammalian adaptation mutations is essential for the timely identification of viruses with increased pandemic potential."

Journal • Infectious Disease • Influenza • Respiratory Diseases